 AIM ImmunoTech Inc NYSEAMERICAN:AIM has announced that the Institutional Review Board IRB of Roswell Park Comprehensive Cancer Center has approved a protocol amendment to Roswell Parks ongoing Phase 12a study evaluating the two-drug combination of AIMs Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate coronavirus COVID-19. AIM ImmunoTech said the IRB-approved amendment calls for randomization of an additional 20 patients. 